US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

CELLINK launches the S.NEST, a high-throughput microbioreactor with real-time monitoring to ensure maximum cell growth and streamlined workflows

CYTENA Bioprocess Solutions, a CELLINK company, has launched the S.NEST™, a state-of-the art microbioreactor that maximizes cell growth while monitoring and analyzing cell conditions from start to finish. Well-known for combining innovative bioscience technologies with best-in-class software development, CYTENA Bioprocess Solutions has developed their new microbioreactor to disrupt the field of cell line development (CLD). Microbioreactors have been instrumental in a string of research breakthroughs in CLD for a range of downstream applications, but with the addition of real-time

CELLINK has been granted a patent for "Cellulose Nanofibrillar Bioink for 3D Bioprinting for Cell Culturing, Tissue Engineering and Regenerative Medicine Applications" from European Patent Office

CELLINK has been granted a patent for its unique cellulose-based bioink technology enabling bioprinting of multiple cell types for tissue engineering and regenerative medicine applications. The patent protection applies to the European market, one of CELLINK’s most important markets.The granted patent from the European Patent Office shows novelty, inventive step, and industrial applicability. This technology is used in CELLINK’s first universal bioink, CELLINK® Bioink, which has expanded into the CELLINK bioink Series (CELLINK® RGD, CELLINK® FIBRIN, CELLINK® SKIN, CELLINK® BONE and CELLINK®

CELLINK Bioprinting moves to Entré Kallebäck

CELLINK’s successful and innovation driven Bioprinting business is in an exciting development phase and will from the beginning of 2022 relocate to the newly built Entré Kallebäck in Gothenburg. The relocation involves co-location of the Swedish part of the business under one roof – from research & development to production and sales and marketing.CELLINK Bioprinting will be the anchor tenant of the building which is strategically located in expansive Kallebäck in central Gothenburg. The newly built property will provide seamless integration in premises that are adapted to the company’s

CELLINK has acquired Visikol, a contract research services company focused on advanced imaging, 3D cell culture assays and digital pathology

CELLINK has acquired Visikol Corp., an American contract research services company offering leading services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharma and biotech companies. CELLINK has acquired all outstanding shares in Visikol for a purchase price of $7.5 million on a cash- and debt-free basis under the assumption that the working capital at closing equals the normalized working capital at closing of which approximately $2.5 million will be paid in 57,911 newly issued shares of series B in CELLINK at a price of SEK 357.60 per share (

CELLINK has entered into an agreement to acquire Nanoscribe, a market leading 3D bioprinting company based on Two-Photon Polymerization technology

CELLINK AB (publ) ("CELLINK") has entered into an agreement with the shareholders of Nanoscribe Holding GmbH ("Nanoscribe"), a market leading and award-winning German company focusing on development of high-precision 3D printers based on Two-Photon Polymerization technology (“2PP”), to acquire all outstanding shares on a cash- and debt-free basis, and under the assumption that the working capital at closing equals the normalized working capital, to a purchase price of €34 million and approximately €16 million in earn-outs, in Nanoscribe (the "Acquisition"). Approximately thirty-five percent

Interim report January-March 2021: High organic growth, strengthened gross margin, and strategic acquisitions

First quarter, 2021 · Net sales amounted to MSEK 129.5 (38.0), which corresponded to an increase of 241% (55) compared to the corresponding period previous year, of which 62% (25) was organic growth. · Operating profit before depreciation (EBITDA) amounted to MSEK -34.9 (-5.7), corresponding to a margin of -26.9% (-14.9). The operating profit during the quarter was affected by acquisition costs totaling MSEK 20.5. · Profit/loss for the period amounted to MSEK -47.8 (-33.5), which generated earnings per share after dilution of SEK -0.90 (-0.80). The result was positively affected

CELLINK receives the prestigious gold award for the BIO X6 and wins two design excellence awards for the C.WASH and UP.SIGHT at the iF Design Awards 2021.

CELLINK has been awarded 3 prestigious awards by the iF Design Awards 2021 for design excellence. With these achievements, CELLINK is now in the top 10 of the iF World Design Index for health/medical.The BIO X6™ bioprinter has been awarded the coveted iF gold award for its innovative and cutting-edge design, a feat achieved by less than 1 percent of entries. CELLINK took home two additional design awards for the UP.SIGHT™ single cell dispenser and C.WASH™ plate washing system. This year’s achievements place CELLINK among the top 10 winners in the health/medical category between 2017-

Invitation to CELLINKs digital Capital Markets Day on May 12, 2021 with focus on the bioconvergence agenda

CELLINK invites investors, analysts, shareholders, and media to a digital Capital Markets Day (CMD) on Wednesday May 12, 2021 at 2-5pm (CEST).We are the frontrunners in the evolving life science universe where we together with our customers develop game-changing solutions by combining biology and technology through our agenda for bioconvergence. CELLINK creates the future of medicine by providing technologies, products, and services for our customers to create, understand and master biology. Please join us during our CMD and explore our bioconvergence agenda, get to know our business

CELLINK has entered into an agreement to acquire MatTek, the global leader in in-vitro technology and alternative drug testing models

CELLINK AB (publ) ("CELLINK") has entered into an agreement with the shareholders of MatTek Corporation ("MatTek"), an American company focusing on advanced in-vitro technology for clinical and pre-clinical studies offering in-vitro human tissue model innovation, cell isolation and cell culture, to acquire all outstanding shares in MatTek for a purchase price on a cash- and debt-free basis of $68 million (the "Acquisition"). Twenty percent of the purchase price will be paid in newly issued shares of series B in CELLINK (the “Consideration Shares”) and the remaining purchase price in cash.

Year-end report 19/20: Continued strong organic growth, positive result and strategic investments for the future

Fifth quarter (September – December 2020, 4 months) · Net sales amounted to SEK 239,216 thousand (SEK 50,189 thousand), which corresponds to an increase of 377% (118%) compared to the corresponding period a year earlier, of which 73% (47%) was organic growth. The acquisition of Scienion has since September 1, 2020 contributed with SEK 152,176 thousand in sales. · Operating profit before depreciation (EBITDA) amounted to SEK 40,414 thousand (SEK -15,567 thousand), corresponding to a margin of 16.9% (-31.0%). · Profit for the period amounted to SEK 13,219 thousand (SEK -18,895

Invitation to CELLINK’s earnings call – Year-end Report 2019/2020

On February 25, 08.00 (CET) CELLINK will publish the Year-end Report 2019/2020 and will also arrange an earnings call, 14:00 (CET) the same date. The earnings call will be available afterwards on the company’s website Investor section.Before the start of the conference call the earnings call presentation will be available on the company's website  Investor section. The presentation will be held in English. Date: Thursday, February 25, 2021. 14:00 (CET)For audio: +46 8 502 439 36  Conference ID: 888 731 010#For video:

There are no items matching the current filter
There are no more items matching the current filter
Back to top